Endo Launches Combination Ibuprofen-Famotidine Tablets

Endo family of businesses (Par Pharmaceutical, Inc. in particular) have announced a generic launch of Duexis tablets 800 mg/26.6 mg, the version in which the active pharmaceutical ingredient of Duexis is famotidine.

"It is our privilege to offer patients and healthcare providers budget-friendly options and reinforce our image as one of the trusted and proven producers of injectables," said Scott Sims, the Group Executive Vice President of Endo Generics and Injectables Solution.

Individual medicine given along with the combination medication is not only used to bring relief to signs and symptoms of rheumatoid arthritis and osteoarthritis but also helps in lowering the risk of generation of ulcers of the stomach and upper intestines, which people might suffer from ibuprofen alone.

As per the record of IQVIA, the retail sales of ibuprofen-famotidine tablets reached roughly $49 million within 12 months, reported on December 31, 2023.

Duexis is a brand trademarked by Horizon Therapeutics USA, Inc.

Endo is a pharmaceutical company specializing in providing several great medications that meet high-quality standards. We assist in improving the lives of patients across the country.